156 related articles for article (PubMed ID: 35481133)
1. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.
Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
Explor Res Clin Soc Pharm; 2021 Jun; 2():100021. PubMed ID: 35481133
[TBL] [Abstract][Full Text] [Related]
2. Prescribing of disease modifying agents in older adults with multiple sclerosis.
Talwar A; Earla JR; Hutton GJ; Aparasu RR
Mult Scler Relat Disord; 2022 Jan; 57():103308. PubMed ID: 35158421
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.
Earla JR; Hutton GJ; Thornton JD; Aparasu RR
Mult Scler Relat Disord; 2020 Oct; 45():102334. PubMed ID: 32629400
[TBL] [Abstract][Full Text] [Related]
4. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.
Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
Patient Prefer Adherence; 2020; 14():2187-2199. PubMed ID: 33177813
[TBL] [Abstract][Full Text] [Related]
5. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
Li J; Chikermane SG; Earla JR; Hutton GJ; Aparasu RR
Mult Scler Relat Disord; 2022 Apr; 60():103703. PubMed ID: 35278846
[TBL] [Abstract][Full Text] [Related]
6. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis.
Earla JR; Hutton GJ; Thornton DJ; Chen H; Johnson ML; Aparasu RR
Pharmacotherapy; 2021 May; 41(5):440-450. PubMed ID: 33641232
[TBL] [Abstract][Full Text] [Related]
7. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Johnson ML; Aparasu RR
Pharmacotherapy; 2023 Jun; 43(6):473-484. PubMed ID: 37157135
[TBL] [Abstract][Full Text] [Related]
8. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data.
Earla JR; Paranjpe R; Kachru N; Hutton GJ; Aparasu RR
Res Social Adm Pharm; 2020 Dec; 16(12):1670-1676. PubMed ID: 32171597
[TBL] [Abstract][Full Text] [Related]
9. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
11. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
[TBL] [Abstract][Full Text] [Related]
12. Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses: A Retrospective Analysis.
Vieira MC; Li Y; Meng X; Zhou H; Piao OW; Kutz C; Conway D
Int J MS Care; 2021; 23(2):73-78. PubMed ID: 33880083
[TBL] [Abstract][Full Text] [Related]
13. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
14. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
15. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
Vieira MC; Conway D; Cox GM; Peeples M; Bensimon AG; Macheca M; Herrera V
Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
[No Abstract] [Full Text] [Related]
16. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
17. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
18. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
19. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
20. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
